Acceleron Announces Initiation of PULSAR Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced the initiation of the PULSAR Phase 2 trial of sotatercept for the treatment of patients with pulmonary arterial hypertension (PAH), a chronic and life-changing disease that can lead to heart failure.

As quoted in the press release:

“There is a real need for new treatment options that have the potential to improve survival for PAH patients,” said David Badesch, M.D., the Director of the Pulmonary Hypertension Program at the University of Colorado and Chair of the PULSAR Trial Steering Committee. “Based on its novel mechanism and preclinical results, sotatercept, particularly in combination with standard-of-care therapies, could be an important advancement in the future treatment of PAH. I look forward to the results of the trial.”

“The initiation of the PULSAR trial is an important milestone in our newly expanded research and development efforts in pulmonary disease,” said Habib Dable, Chief Executive Officer of Acceleron. “We believe that treatment with sotatercept could restore a vital signaling pathway that is known to be deficient in PAH patients. This is an extremely important trial, as we hope to bring an innovative medicine to the thousands of patients who are suffering from PAH.”

Click here to read the full press release.